JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Search

Anavex Life Sciences Corp

Затворен

СекторЗдравеопазване

3.32 -0.6

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.2800000000000002

Максимум

3.33

Ключови измерители

By Trading Economics

Приходи

4.1M

-5.7M

Служители

34

EBITDA

3.1M

-6.8M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+486.51% upside

Дивиденти

By Dow Jones

Следващи печалби

12.05.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-84M

305M

Предишно отваряне

3.92

Предишно затваряне

3.32

Настроения в новините

By Acuity

50%

50%

180 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.05.2026 г., 23:43 ч. UTC

Значими събития в новините

New Zealand's Unemployment Rate Falls in 1Q

5.05.2026 г., 23:20 ч. UTC

Горещи акции

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5.05.2026 г., 21:48 ч. UTC

Печалби

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5.05.2026 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6.05.2026 г., 00:00 ч. UTC

Пазарно говорене

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5.05.2026 г., 23:39 ч. UTC

Пазарно говорене

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5.05.2026 г., 22:26 ч. UTC

Пазарно говорене

AMD Data-Center Business Continues to Surge -- Market Talk

5.05.2026 г., 22:20 ч. UTC

Пазарно говорене

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5.05.2026 г., 22:08 ч. UTC

Печалби

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5.05.2026 г., 22:07 ч. UTC

Печалби

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5.05.2026 г., 21:48 ч. UTC

Печалби

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5.05.2026 г., 21:48 ч. UTC

Печалби

Pan American Silver 1Q Rev $1.2B >PAAS

5.05.2026 г., 21:42 ч. UTC

Печалби

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5.05.2026 г., 21:38 ч. UTC

Печалби

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5.05.2026 г., 21:30 ч. UTC

Печалби

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5.05.2026 г., 21:29 ч. UTC

Печалби

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5.05.2026 г., 21:26 ч. UTC

Печалби

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5.05.2026 г., 21:25 ч. UTC

Печалби

Alcon Inc. 1Q EPS 39c >ALC.EB

5.05.2026 г., 21:25 ч. UTC

Печалби

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5.05.2026 г., 21:24 ч. UTC

Печалби

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5.05.2026 г., 21:18 ч. UTC

Печалби

Mistras Backs 2026 Rev $730M-$750M >MG

5.05.2026 г., 21:17 ч. UTC

Печалби

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5.05.2026 г., 21:15 ч. UTC

Печалби

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5.05.2026 г., 21:12 ч. UTC

Печалби

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5.05.2026 г., 21:11 ч. UTC

Печалби

SSR Mining 1Q Rev $581.8M >SSRM

5.05.2026 г., 21:10 ч. UTC

Печалби

SSR Mining 1Q Adj EPS $1.15 >SSRM

5.05.2026 г., 21:10 ч. UTC

Печалби

SSR Mining 1Q EPS $1.16 >SSRM

5.05.2026 г., 21:08 ч. UTC

Печалби

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5.05.2026 г., 21:01 ч. UTC

Печалби

Intact Financial 1Q EPS C$4.12 >IFC.T

5.05.2026 г., 21:01 ч. UTC

Горещи акции

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

486.51% нагоре

12-месечна прогноза

Среден 20 USD  486.51%

Висок 20 USD

Нисък 20 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

1

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

180 / 347 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
help-icon Live chat